Open AccessThis article is
- freely available
Recent Developments in Preclinical DNA Vaccination
Department of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa Prefecture 236-0004, Japan
Choju Medical Institute, Toyohashi, Aichi Prefecture 441-8124, Japan
Vaccine Institute, Yokohama, Kanagawa Prefecture 2235-0045, Japan
* Author to whom correspondence should be addressed.
Received: 15 October 2013; in revised form: 22 November 2013 / Accepted: 26 November 2013 / Published: 13 January 2014
Abstract: The advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. For example, it is easy to generate plasmid DNAs, increase their dose during the manufacturing process, and sterilize them. Furthermore, they can be stored for a long period of time upon stabilization, and their protein encoding sequences can be easily modified by employing various DNA-manipulation techniques. Although DNA vaccinations strongly increase Th1-mediated immune responses in animals, several problems persist. One is about their weak immunogenicity in humans. To overcome this problem, various genetic adjuvants, electroporation, and prime-boost methods have been developed preclinically, which are reviewed here.
Keywords: DNA vaccine; genetic adjuvants; electroporation
Citations to this Article
Cite This Article
MDPI and ACS Style
Okuda, K.; Wada, Y.; Shimada, M. Recent Developments in Preclinical DNA Vaccination. Vaccines 2014, 2, 89-106.
Okuda K, Wada Y, Shimada M. Recent Developments in Preclinical DNA Vaccination. Vaccines. 2014; 2(1):89-106.
Okuda, Kenji; Wada, Yoshiyuki; Shimada, Masaru. 2014. "Recent Developments in Preclinical DNA Vaccination." Vaccines 2, no. 1: 89-106.